The Institutional Biosafety Committee is responsible for enforcing policies and guidelines related to university related use of all potentially hazardous biological agents including but not limited to infectious agents, human and non-human primate materials (including established cell lines and stem cells), CDC/USDA select agents and toxins, recombinant or synthetic nucleic acid, clinical trials involving human gene therapy, genetically modified animals and whole plants and animals or animal specimens known to be reservoirs/vectors of zoonotic diseases. It is the policy of the University to provide a safe and healthy work environment. All persons at UCI must abide by the regulatory and policy requirements pertaining to the acquisition and use of these materials for research, teaching, or testing (herein referred to as activities). The Committee ensures that activities involving these agents are conducted in a manner that does not endanger the researcher, laboratory worker, human research subjects, the public or the environment.

The Institutional Biosafety Committee is responsible for:

- Formulating and implementing policies related to the safe use of biological materials, infectious agents and their potential sources, recombinant and synthetic nucleic acids and select agents and toxins under the Federal Select Agent Program;
- Reviewing all research protocols involving biological materials, infectious agents and their potential sources, recombinant and synthetic nucleic acids, select agents and toxins under the Federal Select Agent Program;
- Approving or disapproving such projects based on their hazard potential and proposed containment procedures;
- Establishing, approving and monitoring proper laboratory conditions and procedures required for such projects;
- Reviewing the qualifications and training of investigators and laboratory personnel engaged in such research to ensure the use of appropriate laboratory safety techniques;
- Ensuring the adoption of proper disposal and decontamination procedures;
- Adopting emergency plans that cover accidental spills and personnel contamination resulting from research;
- Ensuring that any significant problems with or violations of the NIH and/or CDC Guidelines are investigated and reported as specified in the NIH Guidelines for Research Involving Recombinant DNA Molecules and the "Biosafety in Microbiological and Biomedical Laboratories" respectively.

The Committee follows the NIH Guidelines for Research Involving Recombinant DNA Molecules on the use of recombinant DNA and human gene transfer and the CDC/NIH guidelines, "Biosafety in Microbiological and Biomedical Laboratories", in addition to implementing more restrictive guidelines as needed.

The Institutional Biosafety Committee meets monthly. Fifty one percent of the voting membership is necessary to establish a quorum to conduct business. Committee members are selected from a pool of faculty with expertise in the properties and safe use of human and non-human primate materials, infectious agents, carcinogens, select agents, recombinant DNA and human gene transfer trials. The pool of faculty selected to serve
on the committee shall meet the requirements specified in the *NIH Guidelines for Research Involving Recombinant DNA Molecules*. Members must attend three-fourths of the meetings or they will be removed from the committee the following year.

The IBC shall consist of at least seven voting members appointed by the Vice Chancellor of Research. The seven voting members must include a members with expertise in recombinant DNA technology, the Director of the University Laboratory Animal Resources department, a member representing the laboratory technical staff, two outside community members and the Biological Safety Officer. Ad-hoc Committee members will be used for various situations as they arise. Members shall serve for a term of three years, which may be renewed by the Vice Chancellor of Research. The Chair shall be designated by the Vice Chancellor of Research and selected from among the faculty representatives on the Committee.

The Committee reports administratively to the Vice Chancellor of A&BS. The Committee receives executive oversight and guidance from the Vice Chancellor of Research; as such, it will routinely update the Vice Chancellor of Research on its activities and seeks advice as needed to resolve research compliance related issues. The Vice Chancellor of Research will in turn apprise the Vice Chancellor of A&BS of any IBC activities or issues that require executive attention.